Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

被引:304
|
作者
Bone, Henry G. [1 ]
Bolognese, Michael A. [2 ]
Yuen, Chui Kin [3 ]
Kendler, David L. [4 ]
Wang, Huei [5 ]
Liu, Yu [5 ]
Martin, Javier San [5 ]
机构
[1] Michigian Bone & Mineral Clin, Detroit, MI 48236 USA
[2] Bethesda Hlth Res Ctr, Bethesda, MD 20817 USA
[3] Univ Manitoba, Winnipeg, MB R3T 2N2, Canada
[4] Univ British Columbia, Vancouver, BC V6T 1Z4, Canada
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
来源
关键词
D O I
10.1210/jc.2007-2814
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Denosumab is an investigational fully human monoclonal antibody against receptor activator of nuclear factor-kappa B ligand, a mediator of osteoclastogenesis and osteoclast survival. Objective: This study evaluated the ability of denosumab to increase bone mineral density (BMD) and decrease bone turnover markers (BTMs) in early and later postmenopausal women with low BMD. Design and Setting: This 2-yr randomized, double-blind, placebo-controlled study was conducted in North America. Participants: Subjects included 332 postmenopausal women with lumbar spine BMD T-scores between -1.0 and -2.5. Interventions: Subjects were randomly assigned to receive denosumab sc, 60 mg every 6 months, or placebo. Randomization was stratified by time since onset of menopause (<= 5 yr or > 5 yr). Main Outcome Measures: The primary end point was the percent change in lumbar spine BMD by dual-energy x-ray absorptiometry at 24 months. Additional end points were percent change in volumetric BMD of the distal radius by quantitative computed tomography; percent change in BMD by dual-energy x-ray absorptiometry for the total hip, one-third radius, and total body; hip structural analysis; percent change in BTMs; and safety. Results: Denosumab significantly increased lumbar spine BMD, compared with placebo at 24 months (6.5 vs. -0.6%; P < 0.0001) with similar results for both strata. Denosumab also produced significant increases in BMD at the total hip, one-third radius, and total body (P < 0.0001 vs. placebo); increased distal radius volumetric BMD (P < 0.01); improved hip structural analysis parameters; and significantly suppressed serum C-telopeptide, tartrate-resistant acid phosphatase-5b, and intact N-terminal propeptide of type 1 procollagen. The overall incidence of adverse events was similar between both study groups. Conclusions: Twice-yearly denosumab increased BMD and decreased BTMs in early and later postmenopausal women.
引用
收藏
页码:2149 / 2157
页数:9
相关论文
共 50 条
  • [1] Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
    Wensel, Terri M.
    Iranikhah, Maryam M.
    Wilborn, Teresa W.
    [J]. PHARMACOTHERAPY, 2011, 31 (05): : 510 - 523
  • [2] Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning From Alendronate Therapy
    Kendler, David L.
    Roux, Christian
    Benhamou, Claude Laurent
    Brown, Jacques P.
    Lillestol, Michael
    Siddhanti, Suresh
    Man, Hoi-Shen
    Martin, Javier San
    Bone, Henry G.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (01) : 72 - 81
  • [3] Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
    Bone, Henry G.
    Bolognese, Michael A.
    Yuen, Chui Kin
    Kendler, David L.
    Miller, Paul D.
    Yang, Yu-Ching
    Grazette, Luanda
    San Martin, Javier
    Gallagher, J. Christopher
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04): : 972 - 980
  • [4] Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
    Sanchez, A.
    Brun, L. R.
    Salerni, H.
    Costanzo, P. R.
    Gonzalez, D.
    Bagur, A.
    Oliveri, B.
    Zanchetta, M. B.
    Farias, V.
    Maffei, L.
    Premrou, V.
    Mansur, J. L.
    Larroude, M. S.
    Sarli, M. A.
    Rey, P.
    Ulla, M. R.
    Pavlove, M. M.
    Karlsbrum, S.
    Brance, M. L.
    [J]. JOURNAL OF OSTEOPOROSIS, 2016, 2016
  • [5] ASSESSMENT OF BONE MINERAL DENSITY AND BONE TURNOVER MARKERS IN POSTMENOPAUSAL WOMEN TRANSITIONED FROM ALENDRONATE TO DENOSUMAB
    Roux, C.
    Brown, J. P.
    Kendler, D. L.
    Lillestol, M.
    Siddhanti, S.
    Man, H. S.
    Martin, J. San
    Bone, H. G.
    Benhamou, C. L.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 10 - 11
  • [6] Denosumab in postmenopausal women with low bone mineral density
    Schwartzman, Julie
    Yazici, Yusuf
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (22): : 2390 - 2390
  • [7] Denosumab in postmenopausal women with low bone mineral density
    McClung, MR
    Lewiecki, EM
    Cohen, SB
    Bolognese, MA
    Woodson, GC
    Moffett, AH
    Peacock, M
    Miller, PD
    Lederman, SN
    Chesnut, CH
    Lain, D
    Kivitz, AJ
    Holloway, DL
    Zhang, C
    Peterson, MC
    Bekker, PJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08): : 821 - 831
  • [8] Denosumab in postmenopausal women with low bone mineral density
    Charles L. Loprinzi
    [J]. Current Oncology Reports, 2006, 8 (4) : 267 - 268
  • [9] Dose–response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis
    T. Nakamura
    T. Matsumoto
    T. Sugimoto
    M. Shiraki
    [J]. Osteoporosis International, 2012, 23 : 1131 - 1140
  • [10] Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women
    Jordan, Natasha
    Barry, Maurice
    Murphy, Eithne
    [J]. CLINICAL INTERVENTIONS IN AGING, 2006, 1 (04) : 377 - 387